Loading...
•
Dec 31, 2021
Bioventus Q4 2021 Earnings Report
Bioventus's financial performance in Q4 2021 was marked by a net loss but revenue growth, driven by strategic acquisitions and organic expansion.
Key Takeaways
Bioventus reported a net sales increase of 32.3% year-over-year to $130.4 million in Q4 2021, driven by acquisitions. However, the company experienced a net loss of $1.9 million, compared to a net income of $2.3 million in the prior year. Adjusted EBITDA increased slightly to $28.5 million from $28.2 million in the prior year.
Net sales increased by 32.3% year-over-year, reaching $130.4 million.
Net loss was ($1.9) million, a decrease compared to the prior year's net income of $2.3 million.
Adjusted EBITDA increased slightly to $28.5 million.
International net sales increased significantly by 71.0% year over year.
Revenue by Geographic Location
Forward Guidance
For the full year 2022, Bioventus expects net sales between $545 million and $565 million, representing a year-over-year growth of approximately 26% to 31%. Adjusted EBITDA is projected to be between $94 million and $107 million, compared to $80.8 million for 2021.
Positive Outlook
- Net sales are expected to grow by approximately 26% to 31% year-over-year.
- Adjusted EBITDA is projected to increase compared to the previous year.
- Focus on achieving double-digit organic revenue growth.
- Delivery on cost-synergy commitments.
- Completion of the anticipated acquisition of CartiHeal.
Challenges Ahead
- The company is not providing guidance for adjusted diluted earnings per share due to the uncertainty of the timing for its potential CartiHeal acquisition.
- Inability to predict with reasonable certainty the impact and timing of acquisition-related expenses.
- Uncertainty regarding accounting fair-value adjustments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...